GEN Exclusives

More »

GEN News Highlights

More »
Jun 6, 2012

Affymetrix, MGH Team Up to Develop Biomarker Tests Using QuantiGene ViewRNA Platform

  • Affymetrix and the Massachusetts General Hospital (MGH) inked a collaboration and licensing agreement to co-develop cancer biomarker tests using Affymetrix’ QuantiGene® ViewRNA Assay platform. Under terms of the deal Affymetrix retains the rights to commercialize any resulting biomarker tests.

    QuantiGene ViewRNA is an in situ hybridization assay that Affymetrix claims can detect a single transcript in a single cell. The firm says the partnership with MGH will provide a route to expanding applications of the technology into the pathology and cancer research markets by providing new multiplex chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH) RNA biomarker assays, which are validated on clinical samples for research applications.

    “Advanced in situ RNA hybridization methods applied to less invasive clinical samples such as FFPE core biopsies, FNAs and CTCs have the potential of becoming powerful new tools to deliver diagnostics that enable the oncologist to personalize patient care,” states George Bers, vp and general manager, gene expression business unit manager—panomics, at Affymetrix.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?